LONDON (Alliance News) - Diurnal Group PLC said on Thursday that, aside from the granting of a patent, it is unsure as to why its share price has tripled.
Shares were 188% higher on Thursday at 62.00 pence each, having earlier hit 78.20p.
The US Patent & Trademark Office has granted Diurnal a second US patent for Chronocort, a cortisol replacement product for the life-long treatment of congenital adrenal hyperplasia and adrenal insufficiency.